ANTIBODIES TO HUMAN TYPE IV COLLAGENASE & ITS INHIBITOR
ANTIBODIES TO HUMAN TYPE IV COLLAGENASE & ITS INHIBITOR
批准号:
3492886
负责人:
CHI-MING LIANG
金额:
$5.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1992
资助国家:
美国
项目状态:
已结题
起止时间:
1992-09-30 至 1993-03-31
关键词:
antibody antigen antibody reaction basement membrane chromatography collagenase diagnosis design /evaluation diagnostic tests enzyme linked immunosorbent assay flow cytometry human tissue hybridomas immunocytochemistry immunoglobulin isotypes immunoprecipitation laboratory mouse method development monoclonal antibody protease inhibitor radioimmunoassay western blottings
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The degradation of basement membrane is important for leukocyte
migration, tissue remodeling, wound healing, angiogenesis and tumor
invasion. Type IV collagen, the major component of basement membrane, is
degraded by type IV collagenase (CIVase) which usually exists in a
latent form. The latent CIVase can be activated in vivo to an active
form whose activity can be regulated by endogenous tissue inhibitor of
metalloproteinase type II (TIMP2). As yet there is no specific
biological, enzymatic or antibody based diagnostic kit commercially
available with acceptable sensitivity for assaying CIVase or TIMP2. We
have recently generated monoclonal antibodies (mAbs) against CIVase.
These mAbs have been characterized by immunoprecipitation, Western blot,
and immunocytochemical labeling of CIVase. We will use a similar
approach to generate anti-TIMP2 mAbs and use these mAbs to develop
quantitative enzyme-linked immunosorbent assay (ELISA),
immunohistochemical and flow cytometry test for examining CIVase and
TIMP2 level in the human body fluids and tissues. In phase II, we will
use these mAbs to evaluate clinical correlations between CIVase and
prognosis levels of patients with diseases involving the breakdown of
basement membrane. We will also isolate cDNA coding for these anti-
CIVase and anti-TIMP2 mAbs that show neutralization activity to generate
single chain antigen-binding proteins or humanized chimeric antibodies.
These molecules will be tested for potential therapeutic uses in wound
healing, angiogenesis, treatment of rheumatoid arthritis and prevention
of cancer metastasis.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
海外基金